Is the period of the unicorn over? What’s gotten into the FDA? And can a NASH drug ever work?
We cowl all that and extra this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Allison DeAngelis joins us to clarify how the extended downturn for biotech shares is stoking nervousness amongst enterprise capitalists. We additionally talk about an FDA plot twist for a novel ALS therapy, a second shot for a once-promising liver drug, and the most recent within the Covid-19 pandemic.
For extra on what we cowl, right here’s the news on biotech VCs; right here’s the story on Intercept Pharmaceuticals; right here’s more on Amylyx Pharmaceuticals; right here’s the latest on Paxlovid prescribing; right here’s where you can find episodes of Color Code; right here’s where you can subscribe to the First Opinion Podcast; and right here’s our complete coverage of the Covid-19 pandemic.
And when you have any suggestions for us — subjects to cowl, company to ask, vocal tics to stop — you possibly can e-mail [email protected].